Testing effectiveness (Phase 2)Active Not RecruitingNCT07491159
What this trial is testing
Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study
Who this might be right for
Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital 106